HC Wainwright Issues Negative Forecast for IONS Earnings

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) – Investment analysts at HC Wainwright dropped their Q3 2027 EPS estimates for Ionis Pharmaceuticals in a research note issued to investors on Thursday, July 30th. HC Wainwright analyst M. Kapoor now expects that the company will post earnings of $0.01 per share for the quarter, down from their previous estimate of $0.04. HC Wainwright currently has a “Buy” rating and a $115.00 target price on the stock. The consensus estimate for Ionis Pharmaceuticals’ current full-year earnings is ($3.67) per share. HC Wainwright also issued estimates for Ionis Pharmaceuticals’ Q4 2027 earnings at $0.18 EPS.

IONS has been the subject of a number of other reports. Canaccord Genuity Group cut their price target on shares of Ionis Pharmaceuticals from $110.00 to $95.00 and set a “buy” rating for the company in a report on Friday, July 10th. Wolfe Research restated a “peer perform” rating on shares of Ionis Pharmaceuticals in a report on Thursday, July 16th. Oppenheimer reaffirmed an “outperform” rating and set a $111.00 price objective on shares of Ionis Pharmaceuticals in a research report on Thursday, April 30th. Morgan Stanley reduced their price target on Ionis Pharmaceuticals from $130.00 to $110.00 and set an “overweight” rating for the company in a report on Friday, July 10th. Finally, Royal Bank Of Canada cut their price objective on shares of Ionis Pharmaceuticals from $100.00 to $85.00 and set an “outperform” rating on the stock in a research report on Monday, July 13th. Eighteen analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $94.65.

Ionis Pharmaceuticals Price Performance

Shares of IONS opened at $54.49 on Tuesday. Ionis Pharmaceuticals has a one year low of $40.03 and a one year high of $86.74. The firm has a market capitalization of $9.06 billion, a price-to-earnings ratio of -15.75 and a beta of 0.36. The stock’s fifty day moving average is $69.13 and its 200-day moving average is $74.35. The company has a debt-to-equity ratio of 3.07, a quick ratio of 7.73 and a current ratio of 7.89.

Hedge Funds Weigh In On Ionis Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in IONS. Brown Brothers Harriman & Co. bought a new position in shares of Ionis Pharmaceuticals in the fourth quarter valued at approximately $27,000. Cassaday & Co Wealth Management LLC bought a new stake in shares of Ionis Pharmaceuticals during the 1st quarter worth $30,000. Quarry LP acquired a new position in Ionis Pharmaceuticals in the 3rd quarter valued at $38,000. Hilton Head Capital Partners LLC bought a new position in Ionis Pharmaceuticals in the 4th quarter worth $47,000. Finally, Laurel Wealth Advisors LLC bought a new position in Ionis Pharmaceuticals in the 4th quarter worth $47,000. Institutional investors and hedge funds own 93.86% of the company’s stock.

Insider Buying and Selling

In related news, Director Michael R. Hayden purchased 5,000 shares of Ionis Pharmaceuticals stock in a transaction on Friday, July 31st. The stock was bought at an average price of $51.60 per share, with a total value of $258,000.00. Following the completion of the transaction, the director directly owned 24,000 shares of the company’s stock, valued at approximately $1,238,400. This represents a 26.32% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Allene M. Diaz sold 10,111 shares of the company’s stock in a transaction dated Tuesday, July 7th. The stock was sold at an average price of $85.42, for a total value of $863,681.62. Following the sale, the director owned 3,811 shares of the company’s stock, valued at approximately $325,535.62. This trade represents a 72.63% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 233,163 shares of company stock valued at $18,316,551. 1.81% of the stock is owned by corporate insiders.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc is a biotechnology company focused on the discovery and development of RNA-targeted therapies designed to modulate gene expression. The company’s proprietary antisense oligonucleotide (ASO) technology enables the selective binding of short synthetic strands of nucleic acids to messenger RNA (mRNA), thereby inhibiting or altering the production of disease-causing proteins. Ionis’ pipeline spans a range of therapeutic areas, including neurological disorders, cardiovascular conditions, metabolic diseases and rare genetic disorders.

Since its founding in 1989 by Dr.